Patents Assigned to UCB Biopharma SRL
-
Patent number: 11524997Abstract: The present invention relates to methods for the treatment of a bone fracture or bone defect. The invention discloses the effective use of an anti-gremlin-1 antibody to accelerate the healing and bridging of bone tissue in segmental gap defects; and demonstrates that inhibitors of gremlin-1 activity may provide improved therapies for treating or preventing fracture non-union.Type: GrantFiled: February 14, 2019Date of Patent: December 13, 2022Assignee: UCB BIOPHARMA SRLInventors: Gareth Charles Glyndwr Davies, Scott John Roberts
-
Patent number: 11518803Abstract: The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.Type: GrantFiled: July 9, 2020Date of Patent: December 6, 2022Assignee: UCB BIOPHARMA SRLInventors: Helene Bon, Joanne Elizabeth Compson, Kate Louise Dixon, Carl Brendan Doyle, Mark Ellis, Maria Margarida Gouveia Sancho, Raymond Anthony Jupp, Lara Kevorkian, Daniel John Lightwood, Diane Marshall, Andrew Charles Payne, Joseph Michael David Rastrick, Monika-Sarah Schulze, Alison Turner, Kerry Louise Tyson
-
Patent number: 11498941Abstract: The present invention is in the field of purification and protein purification in particular. The invention provides improved techniques for the industrial-scale purification of proteins and other biomolecules. More specifically, it relates to a process for the purification of a compound of interest, such as a protein, preferably an antibody or an antibody fragment using a chromatography step, preferably a semi-continuous chromatography step.Type: GrantFiled: July 16, 2018Date of Patent: November 15, 2022Assignee: UCB BIOPHARMA SRLInventor: Michael Harry Rose
-
Patent number: 11492396Abstract: The invention relates to therapeutic uses of antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F in the treatment of dermatological and rheumatological diseases, such as psoriasis, psoriatic arthritis and axial spondyloarthritis.Type: GrantFiled: October 26, 2016Date of Patent: November 8, 2022Assignee: UCB BIOPHARMA SRLInventors: Sophie Glatt, Lucian Ionescu, Margaret Jones, Ruth Oliver, Stevan Graham Shaw, Foteini Strimenopoulou, Venkata Pavan Kumar Vajjah
-
Patent number: 11472879Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.Type: GrantFiled: January 31, 2020Date of Patent: October 18, 2022Assignee: UCB BIOPHARMA SRLInventors: Helene Margaret Finney, Stephen Edward Rapecki, Kerry Louise Tyson, Michael John Wright
-
Patent number: 11472794Abstract: A series of substituted fused bicyclic imidazole derivatives, including benzimidazole derivatives and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.Type: GrantFiled: January 10, 2019Date of Patent: October 18, 2022Assignee: UCB Biopharma SRLInventors: Gareth Neil Brace, Rose Elizabeth Bardell-Cox, Gregory Foulkes, James Richard Frost, Helen Tracey Horsley, Elizabeth Pearl Jones, Fabien Claude Lecomte, James Thomas Reuberson, Monika-Sarah Elizabeth Dorothea Schulze, Richard David Taylor, Wei Tsung Yau, Zhaoning Zhu
-
Patent number: 11466076Abstract: The present disclosure relates to a method of modulating the half-life of a binding domain specific to a serum carrier protein by mutating the sequence and a modulated binding domain specific to a serum carrier protein.Type: GrantFiled: April 28, 2017Date of Patent: October 11, 2022Assignee: UCB BIOPHARMA SRLInventors: Ralph Adams, Sam Philip Heywood
-
Patent number: 11466324Abstract: The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.Type: GrantFiled: January 15, 2019Date of Patent: October 11, 2022Assignee: UCB BIOPHARMA SRLInventors: Adam Samuel Platt, Stephen Edward Rapecki, Mara Fortunato, David Robert Rainey, Jon Leigh Rundle, Paul Alfred Smith, Gillian Fairfull Watt
-
Patent number: 11448655Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Accordingly, these compounds can be used as modulators of TNF. A new assay for identifying compounds with this mechanism of action is also disclosed.Type: GrantFiled: May 26, 2020Date of Patent: September 20, 2022Assignee: UCB BIOPHARMA SRLInventors: James Philip O'Connell, John Robert Porter, Alastair Lawson, Boris Kroeplien, Stephen Edward Rapecki, Timothy John Norman, Graham John Warrellow
-
Patent number: 11427650Abstract: The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab? fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.Type: GrantFiled: January 21, 2019Date of Patent: August 30, 2022Assignee: UCB BIOPHARMA SRLInventors: David Paul Humphreys, Emma Dave, Laura Griffin, Sam Philip Heywood
-
Patent number: 11407835Abstract: The present invention relates to pharmaceutical compositions comprising an antibody or a fragment thereof suitable for freeze-drying (i.e. lyophilizing). The pharmaceutical compositions, which comprise an antibody or an antigen-binding fragment thereof; from 1% to 20% w/v sucrose; an amino acid or a mixture of amino acids; and surfactant, are provided as pharmaceutical compositions for freeze-drying; as freeze-dried (i.e. lyophilized) compositions which can be reconstituted into a solvent at the time of use or as reconstituted liquid formulations ready for administration.Type: GrantFiled: May 11, 2017Date of Patent: August 9, 2022Assignee: UCB BIOPHARMA SRLInventors: Andrew Jeffrey Yates, Jan Ivo Massant
-
Patent number: 11401349Abstract: The present disclosure relates to a multi-specific antibody molecule comprising or consisting of three polypeptides: a) a polypeptide chain of formula (I):(Vxx)nVx-Cx-X-V1; and b) a polypeptide chain of formula (II): (Vyy)nVy-Cy c) a polypeptide of formula (III):V2 wherein Vx represents a variable domain, Vxx represents a variable domain, Cx represents a constant region, X represents a linker, V represents a variable domain, Vy represents a variable domain, Vyy represents a variable domain, Cy represents a constant region, V2 represents a variable domain, nindependently represents 0 or 1, wherein the polypeptide chain of formula (I) and the polypeptide chain of formula (II) is aligned such that the constant regions Cx and Cy are paired and the variable domains Vx and Vy are paired to form a binding domain and optionally a disulphide bond is present between V1 and V2, in particular where a disulphide bond is present.Type: GrantFiled: September 17, 2019Date of Patent: August 2, 2022Assignee: UCB Biopharma SRLInventors: Emma Dave, Sam Philip Heywood, David Paul Humphreys
-
Patent number: 11384136Abstract: The present disclosure relates to a method for the manufacture of recombinant antibody molecules comprising culturing a host cell sample transformed with an expression vector encoding a recombinant antibody molecule; adding an extraction buffer to the sample; and subjecting the sample to a heat treatment step; wherein the pH of the sample is detected after addition of the extraction buffer, and optionally adjusted, to ensure that the pH of the sample is 6 to 9 prior to the heat treatment step.Type: GrantFiled: November 5, 2019Date of Patent: July 12, 2022Assignee: UCB BIOPHARMA SRLInventors: Jean-Pascal Pierre Bilgischer, Philip Jonathan Bassett, Mark Robert Pearce-Higgins, Andrew John Kenny
-
Patent number: 11345760Abstract: The present disclosure relates to a multi-specific antibody molecule comprising or consisting of: a) a polypeptide chain of formula (I): VH—CH1—X—V1; and b) a polypeptide chain of formula (II): VL-CL-Y—V2 and pharmaceutical formulations comprising, for example for use in treatment. The disclosure also provides polynucleotide sequences encoding said multispecific antibody molecules, vectors comprising the polynucleotides and host cells comprising said vectors and/or polynucleotide sequences. There is a provided a method of expressing a multispecific antibody molecule of the present disclosure from a host cell.Type: GrantFiled: June 25, 2015Date of Patent: May 31, 2022Assignee: UCB BIOPHARMA SRLInventors: Pallavi Bhatta, Emma Dave, Sam Philip Heywood, David Paul Humphreys
-
Three-dimensional medical image analysis method and system for identification of vertebral fractures
Patent number: 11341639Abstract: A machine-based learning method estimates a probability of bone fractures in a 3D image, more specifically vertebral fractures. The method and system utilizing such method utilize a data-driven computational model to learn 3D image features for classifying vertebra fractures. A three-dimensional medical image analysis system for predicting a presence of a vertebral fracture in a subject includes a 3D image processor for receiving and processing 3D image data of a 3D image of the subject, producing two or more sets of 3D voxels. Each of the sets of 3D voxels corresponds to an entirety of the 3D image and each of the sets of 3D voxels consists of equal 3D voxels of different dimensions. The system also includes a voxel classifier for assigning the 3D voxels one or more class probabilities each of the 3D voxels contains a fracture using a computational model, and a fracture probability estimator for estimating a probability of the presence of a vertebral fracture in the subject.Type: GrantFiled: November 29, 2018Date of Patent: May 24, 2022Assignee: UCB BIOPHARMA SRLInventor: Joeri Nicolaes -
Patent number: 11315685Abstract: A method of building a machine learning pipeline for predicting the efficacy of anti-epilepsy drug treatment regimens is provided.Type: GrantFiled: January 25, 2017Date of Patent: April 26, 2022Assignee: UCB BIOPHARMA SRLInventors: Kunal Malhotra, Sungtae An, Jimeng Sun, Myung Choi, Cynthia Dilley, Chris Clark, Joseph Robertson, Edward Han-Burgess
-
Patent number: 11292831Abstract: The present invention relates to alpha synuclein binding antibodies and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.Type: GrantFiled: December 13, 2018Date of Patent: April 5, 2022Assignee: UCB BIOPHARMA SRLInventors: Patrick Downey, Kerry Louise Tyson, Marco Kriek, Lorenzo De Lichtervelde, Daniel John Lightwood, David James McMillan, Peter Charles Elliott, Terence Seward Baker
-
Patent number: 11286312Abstract: The present invention relates to heterodimerically-tethered bispecific protein complexes (according to the general formula of A-X:Y-B) and libraries/multiplexes thereof for use in research and therapy and in particular an in vitro/ex vivo method of detecting synergistic biological function of otherwise unknown pairs of targets.Type: GrantFiled: December 1, 2016Date of Patent: March 29, 2022Assignee: UCB BIOPHARMA SRLInventors: Pallavi Bhatta, Laura Starkie, Michael John Wright
-
Patent number: 11261252Abstract: The present disclosure relates to multispecific molecule comprising a binding domain specific to the antigen CD22 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising the same and use of both in treatment, for example the treatment of autoimmune disease.Type: GrantFiled: July 16, 2019Date of Patent: March 1, 2022Assignee: UCB BIOPHARMA SRLInventors: Helene Margaret Finney, Stephen Edward Rapecki, Michael John Wright, Kerry Louise Tyson
-
Patent number: 11261242Abstract: The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.Type: GrantFiled: December 13, 2018Date of Patent: March 1, 2022Assignee: UCB BIOPHARMA SRLInventors: Ralph Adams, Patrick Downey, Terence Seward Baker, Kerry Louise Tyson, Lorenzo De Lichtervelde, Daniel John Lightwood, David James McMillan